Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 06, 2026 08:00 ET | Source: Tenvie Therapeutics, Inc.

Tenvie Therapeutics Announces Dosing of First Subject in Phase 1 Clinical Trial of TNV262, a Fully CNS-Penetrant NLRP3 Inhibitor

First candidate from Tenvie’s product engine to enter clinical developmentPhase 1 first-in-human study to evaluate single and multiple ascending doses of TNV262 in healthy volunteers and persons with...
February 18, 2026 08:00 ET | Source: Tenvie Therapeutics, Inc.

Tenvie Therapeutics Appoints Don O’Sullivan, Ph.D., MBA, as Chief Business Officer

Tenvie Therapeutics appoints Dr. Don O'Sullivan as Chief Business Officer to lead strategic collaborations as the company advances toward the clinic
July 23, 2025 08:40 ET | Source: Tenvie Therapeutics, Inc.

Tenvie Therapeutics Promotes Tony Estrada, PhD, to Chief Executive Officer

Tenvie Therapeutics promotes co-founder Tony Estrada, PhD, to CEO as the CNS-focused biotech advances SARM1 and NLRP3 inhibitors toward the clinic.
January 08, 2025 08:00 ET | Source: Tenvie Therapeutics, Inc.

Tenvie Therapeutics Launches with $200 Million to Deliver Breakthrough Small Molecule Therapies

Advancing a deep pipeline of therapeutics focused on treating neurological, cardiometabolic, and ophthalmic diseases Led by expert R&D leadership team with proven ability to develop therapies for...